NCT02157051View on ClinicalTrials.gov

Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

November 25, 2022

Study Completion Date

February 10, 2027

Conditions
HER2 Negative Breast CarcinomaRecurrent Breast CarcinomaStage IIIA Breast CancerStage IIIB Breast CancerStage IIIC Breast CancerStage IV Breast CancerStage III Breast Cancer
Interventions
BIOLOGICAL

CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine

Given ID

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (1)

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

Sponsors

Collaborators (1)

Breast Cancer Alliance
All Listed Sponsors
collaborator

United States Department of Defense

FED

collaborator

Breast Cancer Alliance

OTHER

lead

University of Washington

OTHER

NCT02157051 - Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer | Biotech Hunter | Biotech Hunter